Short answer
MeiraGTx Holdings plc (MGTX) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Alan M. Sebulsky appointed Class I director effective September 23, 2026, serving through the 2028 annual meeting.
MeiraGTx Holdings plc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Alan M. Sebulsky appointed Class I director effective September 23, 2026, serving through the 2028 annual meeting
- Science and Technology Committee assignment adds biopharmaceutical investment and healthcare industry expertise
- Prior Adage Capital portfolio manager now managing member of Apothecary Capital LLC
- Eligible for standard non-employee director compensation and expected indemnification agreement
- No selection arrangement or related-party transactions disclosed
Item 7.01 · Regulation FD Disclosure
- Alan M. Sebulsky appointed to MeiraGTx’s Board
- Appointment details contained in Exhibit 99.1 press release
- Board addition may affect governance and strategic oversight
Item EX-99.1 · Exhibit EX-99.1
- Board appointment of Alan M. Sebulsky, a healthcare investor with over 40 years’ experience, adds biopharma capital-markets expertise
- Sebulsky previously oversaw a diversified biopharmaceutical portfolio with over $2 billion in assets at Adage Capital Management
- Appointment supports MeiraGTx’s transition toward commercialization and may strengthen strategic, portfolio, and growth oversight
- His board experience includes Jazz Pharmaceuticals, Arrow International, and Parabilis Medicines
- MeiraGTx continues advancing four late-stage clinical programs alongside internally developed manufacturing capabilities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MeiraGTx Holdings plc 8-K filings
Get the next MGTX 8-K as it lands
Follow MGTX for push alerts, or ask the research agent what this filing means.